Animal models have shown that exogenous administration of CSF-1, like GM-CSF, exacerbates the incidence and severity of CIA, while anti-CSF-1 Ab, genetic deletion of CSF-1, and pharmacological inhibitors of CSF1R reduce the severity of experimental arthritis [11, 12, 22, 23]. The gene discussed is CSF2; the disease is arthritic joint disease.